Xtx Topco LTD Puma Biotechnology, Inc. Transaction History

Xtx Topco LTD

$710 Million
Q1 2024

A detailed history of Xtx Topco LTD transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 54,153 shares of PBYI stock, worth $176,538. This represents 0.04% of its overall portfolio holdings.

Number of Shares

54,153

Previous 54,892 1.35%

Holding current value

$176,538

Previous $237,000 21.1%

% of portfolio

0.04%

Previous 0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.29 - $7.4 $3,170 - $5,468	-739 Reduced 1.35%	54,153 $287,000
Q4 2023 Feb 13, 2024	BUY	$2.23 - $4.49 $88,314 - $177,817	39,603 Added 259.03%	54,892 $237,000
Q3 2023 Nov 13, 2023	SELL	$2.63 - $4.09 $166,113 - $258,328	-63,161 Reduced 80.51%	15,289 $40,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $8,239 - $11,345	-3,169 Reduced 3.88%	78,450 $276,000
Q1 2023 May 12, 2023	SELL	$2.21 - $4.82 $28,146 - $61,387	-12,736 Reduced 13.5%	81,619 $252,000

Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $140,553 - $336,798	66,299 Added 236.31%	94,355 $399,000
Q3 2022 Nov 14, 2022	SELL	$2.35 - $3.84 $18,973 - $31,004	-8,074 Reduced 22.35%	28,056 $66,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.3 $41,144 - $82,790	-25,088 Reduced 40.98%	36,130 $103,000
Q1 2022 May 13, 2022	BUY	$2.13 - $3.24 $65,838 - $100,148	30,910 Added 101.99%	61,218 $176,000
Q4 2021 Feb 11, 2022	BUY	$2.85 - $6.58 $86,377 - $199,426	30,308 New	30,308 $92,000
Q3 2021 Nov 12, 2021	SELL	$6.63 - $9.39 $104,124 - $147,469	-15,705 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$8.98 - $11.6 $141,030 - $182,178	15,705 New	15,705 $144,000

Others Institutions Holding PBYI

# of Institutions

Shares Held

29.5M

Call Options Held

842K

Put Options Held

32.2K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $149M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account